#Israel #Caesarea #IceCure Medical #Cryoablation #Rights Offering

IceCure Medical's Rights Offering Announcement

IceCure Medical Ltd., a prominent player in the field of minimally invasive cryoablation technology, has officially announced a significant rights offering aimed at raising up to $10 million. The offering is designed to facilitate investment from its existing shareholders, allowing each holder of ordinary shares to purchase additional shares and warrants for a fraction of their market value.

Key Details of the Rights Offering

As per the announcement made on June 25, 2025, the rights offering is open to all shareholders recorded on July 9, 2025, at 5:00 PM ET. Each shareholder will receive one Subscription Right for every ordinary share they own. These rights will let them subscribe for 0.1703 of a unit, which consists of an ordinary share and a warrant priced at $1.00 per unit. Alternatively, shareholders can opt for a pre-funded warrant plus a separate warrant at a price of $0.9999 per unit.

Shareholders interested in participating need to be aware that no fractional rights or units will be issued, and they must exercise rights for at least one whole unit. The subscription rights will expire on July 28, 2025, at 5:00 PM ET. While the company has the discretion to extend this period, it warns that unexercised rights will have no value after this date.

"The rights offering represents a pivotal moment for IceCure Medical as we aim to secure additional capital to support our operations and repay existing loans," said a representative of the company. This fundraising initiative is particularly crucial as IceCure aims to continue developing its innovative technology for tumor ablation through freezing, which offers a less invasive alternative to traditional surgical procedures.

Financial Backing from Major Shareholders

Epoch Partner Investments Limited, IceCure’s largest shareholder, has pledged its full support for the rights offering. Epoch plans to fully exercise its Subscription Rights and participate in any oversubscription opportunities, potentially amounting to an investment of up to $5 million. This commitment underscores the confidence that major shareholders have in IceCure’s growth prospects and the viability of its cryoablation technology.

The offering follows a previous $2 million unsecured loan from Epoch to IceCure, intended to bolster operational capacity until the rights issue is completed. The proceeds from the rights offering will be utilized to pay back this loan as well as to fund general corporate expenses.

Timeline for Shareholders

For interested shareholders, here are the upcoming critical dates:

• - July 8, 2025: Last day to acquire shares to be eligible for the record date.
• - July 9, 2025: Record date for the rights offering at 5:00 PM ET.
• - July 10, 2025: Distribution of subscription rights begins, and the subscription period opens.
• - July 28, 2025: Last day for shareholders to exercise their subscription rights at 5:00 PM ET.

About IceCure Medical

IceCure Medical Ltd specializes in developing and marketing advanced cryoablation therapy systems that utilize liquid nitrogen for tumor destruction. The technology primarily targets cancers that affect the breast, kidney, lung, and bone, offering a safer, minimally invasive alternative to surgical tumor removal. IceCure’s leading product, the ProSense® system, is approved and marketed worldwide, reflecting the company's commitment to innovative cancer treatment solutions.

This rights offering is part of IceCure’s broader strategy to enhance its product portfolio and increase market penetration amidst escalating competition in the healthcare sector. By engaging directly with their current shareholders, IceCure aims to foster a strong financial foundation to continue their mission in cutting-edge cancer treatments.

The rights offering also demonstrates the company’s proactive steps towards enhancing shareholder value while addressing crucial funding requirements for ongoing and future projects. As a shareholder, assessing the implications of this offering could be pivotal for your investment decision.

Inquiries concerning the rights offering can be directed towards Broadridge Corporate Issuer Solutions, LLC for more information on how to participate effectively.